Xiaodun Li

Xiaodun Li

Auto-generated profile, based on publicly available information

Xiaodun Li

MRC Cancer Unit, Hutchison/MRC Research Centre, University of Cambridge, Cambridge, United Kingdom

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2016 in Nature Genetics
Verified
Journal Article
Open access
PDF file
TCthe Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium
the Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium
MSMaria Secrier
Maria Secrier
XLXiaodun Li
Xiaodun Li
NSNadeera de Silva
Nadeera de Silva
MEMatthew D Eldridge
Matthew D Eldridge
RFRebecca C Fitzgerald
Rebecca C Fitzgerald
Rebecca Fitzgerald and colleagues report the whole-genome sequences of 129 esophageal adenocarcinomas, showing frequent copy number alterations and prevalent mutations in receptor tyrosine kinases concomitant with mitogenic activation. They further characterize mutation signatures and find three distinct molecular subtypes with potential for application to clinical diagnosis and treatment. Esophageal adenocarcinoma (EAC) has a poor outcome, and targeted therapy trials have thus far been disappointing owing to a lack of robust stratification methods. Whole-genome sequencing (WGS) analysis of 129 cases demonstrated that this is a heterogeneous cancer dominated by copy number alterations with frequent large-scale rearrangements. Co-amplification of receptor tyrosine kinases (RTKs) and/or downstream mitogenic activation is almost ubiquitous; thus tailored combination RTK inhibitor (RTKi) therapy might be required, as we demonstrate in vitro. However, mutational signatures showed three distinct molecular subtypes with potential therapeutic relevance, which we verified in an independent cohort (n = 87): (i) enrichment for BRCA signature with prevalent defects in the homologous recombination pathway; (ii) dominant T>G mutational pattern associated with a high mutational load and neoantigen burden; and (iii) C>A/T mutational pattern with evidence of an aging imprint. These subtypes could be ascertained using a clinically applicable sequencing strategy (low coverage) as a basis for therapy selection.

30 July 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
XLXiaodun Li
Xiaodun Li
HFHayley E. Francies
Hayley E. Francies
MSMaria Secrier
Maria Secrier
JPJuliane Perner
Juliane Perner
AMAhmad Miremadi
Ahmad Miremadi
MGMathew J. Garnett
Mathew J. Garnett
Esophageal adenocarcinoma (EAC) incidence is increasing while 5-year survival rates remain less than 15%. A lack of experimental models has hampered progress. We have generated clinically annotated EAC organoid cultures that recapitulate the morphology, genomic, and transcriptomic landscape of the primary tumor including point mutations, copy number alterations, and mutational signatures. Karyotyping of organoid cultures has confirmed polyclonality reflecting the clonal architecture of the primary tumor. Furthermore, subclones underwent clonal selection associated with driver gene status. Medium throughput drug sensitivity testing demonstrates the potential of targeting receptor tyrosine kinases and downstream mediators. EAC organoid cultures provide a pre-clinical tool for studies of clonal evolution and precision therapeutics.

4 February 2019 in Nature Genetics
Verified
Journal Article
Open access
PDF file
TCthe Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium
the Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium
AFAlexander M. Frankell
Alexander M. Frankell
SJSriGanesh Jammula
SriGanesh Jammula
XLXiaodun Li
Xiaodun Li
GCGianmarco Contino
Gianmarco Contino
RFRebecca C. Fitzgerald
Rebecca C. Fitzgerald
Esophageal adenocarcinoma (EAC) is a poor-prognosis cancer type with rapidly rising incidence. Understanding of the genetic events driving EAC development is limited, and there are few molecular biomarkers for prognostication or therapeutics. Using a cohort of 551 genomically characterized EACs with matched RNA sequencing data, we discovered 77 EAC driver genes and 21 noncoding driver elements. We identified a mean of 4.4 driver events per tumor, which were derived more commonly from mutations than copy number alterations, and compared the prevelence of these mutations to the exome-wide mutational excess calculated using non-synonymous to synonymous mutation ratios (dN/dS). We observed mutual exclusivity or co-occurrence of events within and between several dysregulated EAC pathways, a result suggestive of strong functional relationships. Indicators of poor prognosis (SMAD4 and GATA4) were verified in independent cohorts with significant predictive value. Over 50% of EACs contained sensitizing events for CDK4 and CDK6 inhibitors, which were highly correlated with clinically relevant sensitivity in a panel of EAC cell lines and organoids.

6 January 2020 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
ANAyesha Noorani
Ayesha Noorani
XLXiaodun Li
Xiaodun Li
MGMartin Goddard
Martin Goddard
JCJason Crawte
Jason Crawte
LALudmil B. Alexandrov
Ludmil B. Alexandrov
RFRebecca C. Fitzgerald
Rebecca C. Fitzgerald

12 July 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
LVLynsey Vaughan
Lynsey Vaughan
PCPaul A Clarke
Paul A Clarke
KBKaren Barker
Karen Barker
YCYvan Chanthery
Yvan Chanthery
CGClay W. Gustafson
Clay W. Gustafson
LCLouis Chesler
Louis Chesler
Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors

31 August 2017 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
EBEdward Britton
Edward Britton
CRConnor Rogerson
Connor Rogerson
SMShaveta Mehta
Shaveta Mehta
YLYaoyong Li
Yaoyong Li
XLXiaodun Li
Xiaodun Li
ASAndrew D. Sharrocks
Andrew D. Sharrocks
Oesophageal adenocarcinoma (OAC) is one of the ten most prevalent forms of cancer and is showing a rapid increase in incidence and yet exhibits poor survival rates. Compared to many other common cancers, the molecular changes that occur in this disease are relatively poorly understood. However, genes encoding chromatin remodeling enzymes are frequently mutated in OAC. This is consistent with the emerging concept that cancer cells exhibit reprogramming of their chromatin environment which leads to subsequent changes in their transcriptional profile. Here, we have used ATAC-seq to interrogate the chromatin changes that occur in OAC using both cell lines and patient-derived material. We demonstrate that there are substantial changes in the regulatory chromatin environment in the cancer cells and using this data we have uncovered an important role for ETS and AP1 transcription factors in driving the changes in gene expression found in OAC cells. Oesophageal adenocarcinoma is one of the ten most prevalent forms of cancer and is showing a rapid increase in incidence and yet exhibits poor survival rates. Understanding the molecular causes of this type of cancer will enable us develop more effective treatment strategies which will improve survival rates. Here we have investigated how the genes in cancer cells are packaged into chromatin. We then compare this packaging to normal cells and use this information to identify the molecular causes leading to changes in chromatin packaging in cancer cells. We have identified a regulatory factor called AP1 that acts as a molecular switch to alter gene expression and hence cause cells to adopt a cancer fate. Importantly either this regulatory factor or a coregulatory protein from the ETS family is upregulated in the majority of cancer cells. Our study has therefore uncovered an important regulatory pathway that is commonly activated in oesophageal adenocarcinoma cells.